Showing results (131-140 of 179) with videos related to

Sort By:
Pageof 18
Urologic Oncology|September 28, 2021
Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS)Kyla Velaer, I-Chun Thomas, Jaden Yang, et al.
AIDS (London, England)|July 19, 2014
Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patientsKarin J Metzner, Alexandra U Scherrer, Viktor von Wyl, et al.
Small Methods|February 12, 2019
Monitoring Neutropenia for Cancer Patients at the Point of CareHakan Inan, James L Kingsley, Mehmet O Ozen, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 22, 2021
Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificitiesQian Yin, Wong Yu, Caitlin L Grzeskowiak, et al.
The Journal of Infectious Diseases|December 25, 2012
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failureJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
The Journal of Infectious Diseases|December 11, 2024
Viral and Immune Risk Factors of HIV Rebound After Interruption of Antiretroviral TherapyS Gianella, T Yu, R Wang, et al.
The Journal of Antimicrobial Chemotherapy|April 11, 2018
Low prevalence of transmitted HIV-1 drug resistance detected by a dried blood spot (DBS)-based next-generation sequencing (NGS) method in newly diagnosed individuals in Cameroon in the years 2015-16Herbert A Mbunkah, Alex Marzel, Stefan Schmutz, et al.
Swiss Medical Weekly|May 16, 2024
Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy: the SIMPL'HIV open-label, factorial randomised controlled trialAnnalisa Marinosci, Delphine Sculier, Gilles Wandeler, et al.
Plos Medicine|November 10, 2020
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trialDelphine Sculier, Gilles Wandeler, Sabine Yerly, et al.
The Journal of Infectious Diseases|July 27, 2023
Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 WeeksLisa Jörimann, Jasmin Tschumi, Marius Zeeb, et al.
Pageof 18